Palbociclib shows PFS but not (yet?) OS benefit in phase II
By Anette Breindl
Monday, April 7, 2014
SAN DIEGO – Results presented at the of the American Association for Cancer Research (AACR) annual meeting on Sunday from the phase II PALOMA-1 trial of CDK inhibitor palbociclib (Pfizer Inc.) led to plenty of buzz that Pfizer Inc. might file for accelerated approval for the drug, despite the lack of an overall survival (OS) benefit to date. Researchers reported at the plenary session that treatment with the palbociclib doubled progression-free survival of women with metastatic estrogen receptor-positive (ER+) breast cancer in an open-label phase II trial when the drug was added to the standard treatment with the estrogen synthesis inhibitor letrozole.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.